Skip to main content
DFTX
NASDAQ Life Sciences

Definium Therapeutics Doses First Patient in Second Phase 3 Study for Major Depressive Disorder

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$21.56
Mkt Cap
$2.334B
52W Low
$6.03
52W High
$26.25
52W Position info
258% above low
Off High info
18% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

DFTX has more than doubled off its 52-week low of $6.03.

Summary

Definium Therapeutics announced the dosing of the first patient in Ascend, its second Phase 3 pivotal study for DT120 ODT in Major Depressive Disorder, signaling significant progress in its clinical pipeline.


Key Events · Product Development and Regulatory · DFTX

  • Second Phase 3 Study Initiated

    Definium Therapeutics has dosed the first patient in Ascend, its second Phase 3 pivotal study evaluating DT120 ODT for the treatment of Major Depressive Disorder (MDD).

  • Advancement of Lead Candidate

    The Ascend study builds on positive Phase 2b results and is aligned in design with the ongoing Emerge Phase 3 study for MDD and other trials for generalized anxiety disorder.

  • Future Data Readouts

    Topline data from the Ascend study's 12-week double-blind period is anticipated in 2027, following the expected topline readout from the Emerge study in late Q2 2026.


Analysis · DFTX · Life Sciences

Definium Therapeutics has initiated its second pivotal Phase 3 study, Ascend, for DT120 ODT in Major Depressive Disorder (MDD) by dosing the first patient. This marks a significant advancement in the company's lead clinical program, building on positive Phase 2b results and complementing the ongoing Emerge Phase 3 study for MDD. Successful progression through Phase 3 is critical for potential regulatory approval and addresses a substantial unmet medical need in MDD. Investors will now look towards the anticipated topline data from the Emerge study in late Q2 2026, followed by Ascend data in 2027.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DFTX was trading at $21.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.03 to $26.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DFTX - Latest Insights

DFTX
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $35.33 info
Change: -$0.6675 (-2%) info
Market Cap: $4.755B info
DFTX
Nov 09, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $35.36
Real-time Price: $35.33 info
Change: -$0.0225 (-0.06%) info
Market Cap: $4.755B info
DFTX
Sep 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $35.33 info
Change: -$9.67 (-21%) info
Market Cap: $4.755B info
DFTX
Sep 14, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.46
Real-time Price: $35.33 info
Change: -$6.13 (-15%) info
Market Cap: $4.755B info
DFTX
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.39
Real-time Price: $35.33 info
Change: -$4.06 (-10%) info
Market Cap: $4.755B info